

7 July 2011

FDA Circular
No. 2011-003-A

To : **All Parties Concerned**

SUBJECT: **Revision to the Schedule of Fees listed in FDA Circular No. 2011-003 dated 24 June 2011 on the Collection of Legal Research Fee Imposed by Republic Act No. 3870, as Amended by PD 200 and further Amended by PD 1856.**

Below is the revision to the Schedule of Fees listed in FDA Circular No. 2011-003 incorporating the corrections to the affected services and their corresponding Fee and Legal Research Fee.

A. Licensing of Establishment (In Page 4)

	AO 50 s.2001					
	Initial			Renewal		
	Fee	LRF	Total	Fee	LRF	Total
Fees for Licensing of Establishments						
16. Others:						
16.2 Clearance to Import Antibiotics	300.00	10.00	310.00			
16.3 Amendment of LTO or Re-Issuance	500.00	10.00	510.00			

B. Product Registration (In Pages 5 & 6)

1. Drugs :						
1.1 New Drug/Monitored Release	20,000.00	200.00	20,200.00			
7.5 Re-Issuance of CPR (Lost Reconstruction)	300.00	10.00	310.00			
7.8.3 Review by ACB						
g. Protocol Amendment	1,000.00	10.00	1,010.00			
h. Extension of Monitored Release	6,000.00	60.00	6,060.00			
i. Compassionate Special Permit (except drugs for cancer, HIV/AIDS, and other life threatening diseases)	500.00	10.00	510.00			

C. Laboratory Analysis (In Page 7)

CLASSIFICATION							
1.1 Drugs and Antibiotics							
Vitamins							
Vitamin C (Ascorbic Acid)	500.00	10.00	510.00				


SUZETTE H. LAZO, M.D. , FPSECP
Acting Director IV